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Abstract 
Targeted massively parallel sequencing (TMPS) has been used in genetic 
diagnosis for Mendelian disorders. In the past few years, the TMPS has 
identified new and already described genes associated with primary ovarian 
insufficiency phenotype. Here, we performed a targeted gene sequencing to 
find a genetic diagnosis in idiopathic cases of Brazilian POI cohort. A custom 
SureSelectXT DNA target enrichment panel was designed and the sequencing 
was performed on Illumina NextSeq sequencer. We identified one homozygous 
1-bp deletion variant (c.783delC) in the GDF9 gene in one patient with POI. The 
variant was confirmed and segregated using Sanger sequencing. The 
c.783delC GDF9 variant changed an aminoacid creating a premature 
termination codon (p.Ser262Hisfs*2). This variant was not present in all public 
databases (ExAC/gnomAD, NHLBI/EVS and 1000 Genomes). Moreover, it was 
absent in 400 alleles from fertile Brazilian women screened by Sanger 
sequencing. The patient’s mother and her unaffected sister carried the 
c.783delC variant in a heterozygous state, as expected for an autosomal 
recessive inheritance. Here, the targeted massively parallel sequencing 
identified the first homozygous 1-bp deletion variant in GDF9. This finding 
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reveals a novel inheritance pattern of pathogenic variant in GDF9 associated 
with POI, thus improving the genetic diagnosis of this disorder.   
 
Keywords: GDF9, Primary ovarian insufficiency, Targeted massively parallel 
sequencing, female infertility 
 
Introduction  
 
Primary ovarian insufficiency (POI), also known as premature ovarian failure 
(POF), results in amenorrhea, hypoestrogenism, infertility, and elevated 
gonadotropin levels (1, 2). The impairment of ovarian function could be induced 
by several factors, such as X chromosome abnormalities, genetic and 
environmental conditions. Several genes known to be involved in the 
recruitment, development, and maturation of the follicles and their constituent 
oocytes have been implicated in POI (2). Bone morphogenic proteins (BMPs), 
growth differentiation factors (GDFs), and neurotrophic factors (NGF, BDNF, 
and GDNF) are few types of growth factors associated with the follicular 
development pathway (2). 
Targeted massively parallel sequencing has been shown to be a powerful tool 
to elucidate the genetic origin of the POI phenotype. Here, we describe the first 
homozygous 1-bp deletion in the GDF9 gene revealed by targeted gene 
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massively parallel sequencing as a cause of primary ovarian insufficiency in one 
woman born to consanguineous parents. 
 
Patients and methods 
Case report 
Approval from the institutional review board and written informed consent from 
all subjects were obtained before blood collection for DNA analysis. This study 
was approved by the Ethics Committee of Hospital das Clínicas, University of 
São Paulo Medical School, Brazil (protocol number 2015/12837/1.015.223). 
From a cohort of 48 sporadic POI cases, the proband was selected for 
molecular analysis, following clinical criteria such as high levels of 
gonadotropins (FSH>40 U/L), hypoestrogenism, absence of spontaneous 
menarche and breast development, absence of FMR1 premutation, and 
autoantibodies. At first appointment, a 19-year-old woman had normal height 
and low weight (151 cm and 32 Kg). Breast development and pubic hair were at 
Tanner II and III, respectively. The karyotype was 46,XX, as determined by the 
analysis of 50 metaphases. Basal serum gonadotropin levels were elevated in 
the proband (FSH = 87 U/L and LH = 51 U/L), whereas serum estradiol was low 
(<13 pg/ml).  
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The patient was treated with conjugated estrogens daily followed by 
progesterone replacement in the first 12 days of the month, resulting in 
complete breast development and normal menstrual cycle. 
Molecular Analyses 
Genomic DNA was extracted from peripheral blood leukocytes using standard 
procedures. A custom SureSelectXT DNA target enrichment panel was designed 
using SureDesign tools (Agilent Technologies Santa Clara, CA, USA). Based on 
female and male gonadal development and function, 284 known and candidate 
genes were selected. All exons and 25 base pairs of intronic flanking sequence 
were included. The proband’s library was prepared according to the SureSelect 
XT Target Enrichment Protocol (Agilent Technologies Santa Clara, CA, USA). 
Sequencing was performed on a NextSeq 500 next-generation sequencer 
(Illumina San Diego, CA, USA). Alignment of raw data and variant calling were 
performed following the steps described by França and collaborators (3). The 
allelic variants identified were classified according to the American College of 
Medical Genetics and Genomics and the Association for Molecular Pathology 
(ACMG/AMP) (4).   
The selected variant was confirmed by Sanger sequencing in the patient and 
her family. Primers flanking the GDF9 mutation (exon3:c.783delC) 
(ENSG00000164404/NM_005260.5) were used for PCR amplification. All PCR 
products were sequenced using BigDye terminator v3.1 cycle sequencing kit 
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followed by automated sequencing using the ABI PRISM 3130xl (Applied 
Biosystems, Foster City, CA). Moreover, Sanger sequencing was performed to 
evaluate 200 fertile Brazilian women controls for the putative damaging variant 
found in this patient. 
Results 
Following filter criteria, we included only coding or splicing variants and variants 
expected by in silico prediction to be disease-causing, which were absent or 
present with minor allele frequency lower than 0.1% in the population databases 
(1000Genomes, ExAC, NHLBI/EVS). The targeted sequencing panel was able 
to identify one homozygous GDF9 variant in the proband. The c.783delC GDF9 
variant is located in exon 3; it changes a serine to histidine at the position 262 
and creates a premature termination codon (NM_005260.5 
(GDF9_i001):c.783delC:p.Ser262Hisfs*2), as predicted by the Mutalyzer 
analysis. The mean coverage depth of the targeted regions in panel sequencing 
data was 145x (SD±66x), with at least 99.38% of the sequenced bases covered 
more than 10-fold. Moreover, the number of total sequenced reads in the 
proband was 1,610,860 of which 99.72% corresponded to mapped reads. A 
total of 888 variants were called before filtering, of which eight variants were 
indels and 880 variants were SNVs.  
Sanger sequencing confirmed the c.783delC GDF9 variant in a homozygous 
state in the patient and in a heterozygous state in her mother and her fertile 
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sister. This variant was absent from all public databases [Genome and Exome 
Aggregation Consortium (ExAC/gnomAD), in the NHLBI Exome Sequencing 
Project (ESP) Exome Variant Server (EVS) and the Internacional Genome 
Sample Resource-1000 Genomes Project]. Moreover, the variant was not 
present in 400 alleles from fertile Brazilian women and in 609 elderly Brazilians 
exomes from ABraOM (Online Archive of Brazilian Mutations) database (5). 
Discussion 
The TGF-β superfamily contains more than 35 members in vertebrates, 
including TGF-βs, BMPs (bone morphogenetic proteins), GDFs (growth 
differentiation factors), activins, inhibins, and mullerian inhibiting hormone (6).  
Some members of this family, such as GDF9 and BMP15, play different 
functions in the ovary by regulating somatic cell function and female fertility (6). 
As visualized by in situ hybridization analysis, GDF9 and BMP15 mRNAs are 
expressed specifically in the mouse oocyte of the preantral follicle type, but not 
in the primordial follicle. After these stages, expression of both persists in the 
oocyte during folliculogenesis and in ovulated oocytes (7), suggesting a 
functional relevance of these factors in ovary development.  
In mice, the Gdf9 null model displayed the role of GDF9 in ovarian function. 
Gdf9-null female mice were infertile due to a block at the primary follicle stage 
(8). Their ovaries showed a block in growth and proliferation of granulosa cells, 
lack of theca layer development and oocyte defects, which included oocyte 
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meiotic competence abnormalities and larger than normal growth of the oocyte 
(8, 9). In contrast, Gdf9-null male mice are fertile, in addition to heterozygous 
Gdf9+/- females (8).  
Furthermore, sheep have also proved a valuable model to elucidate the 
importance of GDF9 in female reproductive function (10). In Belclare and 
Cambridge sheep, GDF9577F heterozygous mutations are associated with 
increased ovulation rate, resulting in larger litter size than normal whereas 
homozygous carriers, in both breeds, are infertile (11). 
In humans, all the GDF9 mutations described so far in different POI cohorts are 
heterozygous missense variants (12). The mutational screening of GDF9 in 127 
Indian women with POI reported two rare heterozygous missense mutations 
(c.199A>C and c.646G>A) in six patients of the cohort. Both missense 
mutations are localized in propeptide region of GDF9 protein, and was identified 
in women with secondary amenorrhea (13). In 2006, Veitia’s group have 
identified one GDF9 heterozygous transversion c.557C>A in the proregion, 
leading to the change p.Ser186Tyr, in one patient with secondary amenorrhea 
from a European cohort of 203 women with POI (14). GDF9 mutation was also 
found in a United States cohort as a rare explanation for POI. Among 61 
subjects, the majority of them Caucasian, one heterozygous missense variant 
(c.307C>T) in a highly conserved proprotein region was identified 
(p.Pro103Ser) (15). In contrast with previous described heterozygous missense 
mutations, we report the first homozygous 1-bp deletion (c.783delC) in GDF9 
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gene in one Brazilian patient with primary amenorrhea, a more severe 
phenotype. This variant followed the guideline of The American College of 
Medical Genetics and Genomics (ACMG) to be considered pathogenic: it was 
absent from all international databases (1000Genomes, NHLBI/EVS, ExAC and 
gnomAD) and Brazilian controls; it segregated with disease in affected 
members, and was absent in unaffected family members; it occurred in a gene 
definitively known to cause the disease, and was a null variant in a gene where 
loss-of-function is a known mechanism of disease (4).  
As previously shown, all heterozygous missense mutations in the GDF9 gene 
were reported in patients with secondary amenorrhea (13, 14, 15) suggesting a 
correlation between a more severe phenotype, as primary amenorrhea, and the 
loss-of-function variant. Moreover, consistent with Mendelian expectations for 
an autosomal-recessive mode of inheritance, the patient’s mother, whom had 
normal ovarian function and had four children, was heterozygous for the same 
mutation demonstrating that some heterozygous GDF9 variants would not 
induce POI. Thus, we can suggest that POI phenotype induced by GDF9 
mutations may have an autosomal dominant or recessive inheritance pattern. 
According to Prosite_SIB database of protein domain, the TGF-beta domain 
region in GDF9 is localized between 316 and 454 amino acids. Furthermore, 
mutations in the proregion can affect the processing of proregion cleavage and 
could compromise normal growth and maturation of ovarian cells. Interesting, all 
described mutations were localized in the propeptide region of GDF9 as well as  
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the variant reported here (p.Ser262Hisfs*2), and therefore could result in a 
truncated protein missing a TGF-beta domain. 
In conclusion, we report the first homozygous 1-bp deletion in GDF9. This 
finding reveals a novel inheritance pattern of a pathogenic variant in GDF9 
associated with POI, thus improving the genetic diagnosis of this disorder. 
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Legend 
Figure 1: The GDF9 homozygous pathogenic variant c.783delC found in the 
proband. (A) Family Pedigree. The black arrow indicates the proband (II-1). 
Pedigree numbers of individuals are indicated above the symbols. (B) 
Screenshots from the Integrative Genomics Viewer of targeted sequencing data 
from the proband (II-1). On top, the [hg19] genomic coordinates shown on the 
screen. In the middle section, gray bars represent sequencing reads with a 
histogram of individual base coverage above the reads. The red arrow indicates 
the homozygous deletion, which is clearly visible in the middle of the panel as a 
region of decreased sequencing coverage. (C) The electropherogram confirmed 
homozygous c.783delC (red arrow on nucleotide peak of interest) in II-1 and 
heterozygous in mother and sister (I-2 and II-3). WT denotes the wild-type allele 
and MT indicates the c.783delC variant. An asterisk indicates samples utilized 
for targeted massively parallel sequencing (TMPS); POI: primary ovarian 
insufficiency. 
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